journal article·2024-11

Engineered‐Doping Strategy for Self‐Sufficient Reactive Oxygen Species Blossom to Amplify Ferroptosis/Cuproptosis Sensibilization in Hepatocellular Carcinoma Treatment

Jiahe Hu, Jiuxin Zhu, Kuan Wang, Xiuwei Yan, Lei Xu, Xiaoling Zhang, He Ding, Piaoping Yang, Shaoshan Hu, Rui Xie

Advanced Functional Materials· Volume 34· Issue 46
Publisher page

Abstract

Abstract Ferroptosis and cuproptosis are emerging modes of programmed cell death and have been increasingly used to eliminate tumor cells. However, converting ferroptosis/cuproptosis into effective treatments is challenging because of the inherent antioxidant and plasma membrane repair systems and inefficient copper ion delivery. Herein, an engineered doping method is developed to encapsulate ZnO2 with Cu2+‐doped ZIF‐8 and modify the surface by transferrin (Tf). In the resulting ZnO2@Cu/ZIF‐8‐Tf nanosystem, Tf specifically binds to transferrin receptors for targeting and aggregation. In the tumor microenvironment, Cu2+/Fe3+ is released from the nanosystem and reacted with glutathione (GSH) to produce Cu+/Fe2+. Excessive accumulation of Cu+ interfered with the tricarboxylic acid cycle and induced coproptosis. Furthermore, the additional Fe2+ caused iron overload and enhanced ferroptosis. ZnO2 supplied hydrogen peroxide to mediate the overproduction of reactive oxygen species (ROS). Moreover, the depletion of GSH deactivated glutathione peroxidase 4 (GPX4) and inhibited the system Xc−‐GSH‐GPX4 pathway, and the amplified ROS triggered lipid peroxidation and reprogrammed lipid metabolism, causing malfunctioning of both antioxidant and membrane repair systems. In summary, the ferroptosis/cuproptosis pathways are activated at multiple levels in the ZnO2@Cu/ZIF‐8‐Tf nanosystem, which ensures its outstanding antitumor effect.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Extracellular vesicles in disease · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Digestive Internal Medicine Harbin Medical University Cancer Hospital 150 Haping Road Harbin Heilongjiang 150081 P. R. China

Department of Pharmacology State‐Province Key Laboratories of Biomedicine‐Pharmaceutics of China Key Laboratory of Cardiovascular Medicine Research Ministry of Education College of Pharmacy Harbin Medical University 157 Baojian Road Harbin Heilongjiang 150081 P. R. China

Department of Gastrointestinal Surgery Harbin Medical University Cancer Hospital 150 Haping Road Harbin Heilongjiang 150081 P. R. China

Cancer Center Department of Neurosurgery Zhejiang Provincial People's Hospital Affiliated People's Hospital Hangzhou Medical College 158 Shangtang Road Hangzhou Zhejiang 310014 P. R. China

Laboratory of Superlight Materials and Surface Technology Ministry of Education College of Material Sciences and Chemical Engineering Harbin Engineering University 145 Nantong Street Harbin Heilongjiang 150001 P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Heilongjiang Province · China Postdoctoral Science Foundation · Heilongjiang Postdoctoral Science Foundation

References (75)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1038/s41572-020-00240-310.1038/s41572-020-00240-3 ↗
3. 10.3322/caac.2116110.3322/caac.21161 ↗
4. 10.1016/S0140-6736(22)01200-410.1016/S0140-6736(22)01200-4 ↗
5. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
6. 10.1038/s41571-020-00462-010.1038/s41571-020-00462-0 ↗
7. 10.3389/fcell.2022.87302910.3389/fcell.2022.873029 ↗
8. 10.1038/s41580-020-00324-810.1038/s41580-020-00324-8 ↗
9. 10.1002/hep.2825110.1002/hep.28251 ↗
10. 10.1146/annurev-pathol-042320-02584010.1146/annurev-pathol-042320-025840 ↗
11. 10.1155/2022/782319110.1155/2022/7823191 ↗
12. 10.1038/s41589-019-0462-810.1038/s41589-019-0462-8 ↗
13. 10.1002/ijc.2815910.1002/ijc.28159 ↗
14. 10.1186/s13046-023-02720-210.1186/s13046-023-02720-2 ↗
15. 10.1126/science.abf052910.1126/science.abf0529 ↗
16. 10.1002/adfm.20240202210.1002/adfm.202402022 ↗
17. 10.1039/d0mt00156b10.1039/d0mt00156b ↗
18. 10.3389/fimmu.2022.98915610.3389/fimmu.2022.989156 ↗
19. 10.1002/adma.20220473310.1002/adma.202204733 ↗
20. 10.1002/adhm.20230253710.1002/adhm.202302537 ↗
21. 10.1016/j.cell.2022.06.00310.1016/j.cell.2022.06.003 ↗
22. 10.3389/fcell.2020.59022610.3389/fcell.2020.590226 ↗
23. 10.1002/med.1000810.1002/med.10008 ↗
24. 10.7150/thno.3941210.7150/thno.39412 ↗
25. Li H. · Trends Pharmacol. Sci. · 2002 · 23 · 9
26. 10.1080/17425247.2022.208310610.1080/17425247.2022.2083106 ↗
27. 10.3389/fphys.2019.0013910.3389/fphys.2019.00139 ↗
28. 10.1038/s41570-021-00310-410.1038/s41570-021-00310-4 ↗
29. 10.1038/s41529-021-00192-310.1038/s41529-021-00192-3 ↗
30. 10.1016/j.nantod.2023.10193210.1016/j.nantod.2023.101932 ↗
31. 10.1002/anie.20180566410.1002/anie.201805664 ↗
32. 10.1021/acsnano.8b0938710.1021/acsnano.8b09387 ↗
33. 10.1021/acs.nanolett.0c0262210.1021/acs.nanolett.0c02622 ↗
34. Li S. L. · Adv. Funct. Mater. · 2021 · 1 · 31
35. 10.3847/1538-4357/ab5f0810.3847/1538-4357/ab5f08 ↗
36. 10.1155/2016/753085310.1155/2016/7530853 ↗
37. 10.7150/thno.3983110.7150/thno.39831 ↗
38. 10.1021/acsami.1c1459810.1021/acsami.1c14598 ↗
39. Sakho E. H. M. · Micro and Nano Technologies · 2017 · 139 · 37
40. 10.1038/ncomms133810.1038/ncomms1338 ↗
41. 10.1021/acs.biochem.8b0000610.1021/acs.biochem.8b00006 ↗
42. 10.1016/j.freeradbiomed.2018.06.03710.1016/j.freeradbiomed.2018.06.037 ↗
43. 10.1016/S0092-8674(04)00130-810.1016/S0092-8674(04)00130-8 ↗
44. 10.5114/wo.2014.4713610.5114/wo.2014.47136 ↗
45. 10.2967/jnumed.109.06898110.2967/jnumed.109.068981 ↗
46. 10.3390/biom1010142910.3390/biom10101429 ↗
47. 10.1016/j.mam.2008.08.00610.1016/j.mam.2008.08.006 ↗
48. 10.1002/adfm.20230933810.1002/adfm.202309338 ↗
49. 10.1002/adhm.20220294910.1002/adhm.202202949 ↗
50. 10.1016/j.jconrel.2021.02.03010.1016/j.jconrel.2021.02.030 ↗
51. Ding H. · Adv. Funct. Mater. · 2023 · 42
52. 10.1021/acsami.1c0327710.1021/acsami.1c03277 ↗
53. 10.1002/advs.20220123210.1002/advs.202201232 ↗
54. 10.1016/j.jhazmat.2014.04.05410.1016/j.jhazmat.2014.04.054 ↗
55. 10.1038/168079a010.1038/168079a0 ↗
56. 10.1002/adma.20200742610.1002/adma.202007426 ↗
57. 10.1021/jacs.9b0350310.1021/jacs.9b03503 ↗
58. 10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
59. 10.1172/jci.insight.13274710.1172/jci.insight.132747 ↗
60. 10.1038/s41422-022-00653-710.1038/s41422-022-00653-7 ↗
61. 10.1007/s10495-023-01928-z10.1007/s10495-023-01928-z ↗
62. 10.1080/15384101.2017.128258610.1080/15384101.2017.1282586 ↗
63. 10.3390/ijms1601092410.3390/ijms16010924 ↗
64. 10.3390/ijms1911363410.3390/ijms19113634 ↗
65. 10.2217/fon.10.1110.2217/fon.10.11 ↗
66. 10.1038/s41569-022-00735-410.1038/s41569-022-00735-4 ↗
67. 10.3390/nu1403070010.3390/nu14030700 ↗
68. 10.1016/j.molcel.2022.05.00110.1016/j.molcel.2022.05.001 ↗
69. Tang D. · Hepatology · 2023 · 10 · 1097
70. 10.1038/nature1347510.1038/nature13475 ↗
71. 10.1016/j.cbi.2015.01.02310.1016/j.cbi.2015.01.023 ↗
72. 10.1021/acsnano.9b0030010.1021/acsnano.9b00300 ↗
73. 10.1080/15548627.2021.191101610.1080/15548627.2021.1911016 ↗
74. 10.1093/nar/gkac93510.1093/nar/gkac935 ↗
75. 10.1093/nar/gkac100010.1093/nar/gkac1000 ↗